Page 16 - Rna News Today

Bristol Myers agrees to pay Avidity $60 million in cash and also will purchase about $40 million of Avidity common stock at $7.88 a share.

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

A leading provider of innovative molecular biology solutions, announces the launch of its EchoLUTION FFPE RNA Kit.

Viome builds at-home tests, shipping direct to its customers, which are designed to help people formulate a better understanding of their health.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) will be posting its quarterly earnings results on Monday, November 6th. Avidity Biosciences (NASDAQ:RNA – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.18. The […]

When, where, and why do diseases jump from animals to people? A new project will monitor how changing seasons, land use, and human behavior influence viral outbreaks in wild rodent populations, to identify hotspots with high potential for spillover into people.

Bifidobacteria in gut are important in immune system and fighting cancer

Considered a pipe dream not too long ago, research on RNA therapeutics is progressing rapidly. Now a new manufacturing protocol will help researchers to advance the technology.

We took the time to speak with Amy Walker, VP of research, at biotechnology company 4basebio to discuss if synthetic DNA templates represent the future of mRNA production.

Even after the runaway success of mRNA vaccines against COVID-19, the pathway to approval for upcoming would-be mRNA therapeutics has yet to be laid out.